Many melanoma patients are treated with drugs called BRAF or MEK inhibitors that specifically target the mutant proteins created in cancerous tumors. These inhibitors can block […]
A new paper in Annals of Neurology describes the approach, structure, and launch of the HEALEY ALS Platform Trial—the first platform trial for amyotrophic lateral sclerosis […]
Women remain underrepresented in leading cardiovascular clinical trials, which corresponds with underrepresentation and a lack of gender diversity among presenters at scientific meetings, according to a […]
Cancer patients rarely die from the primary tumor, but rather from the metastases—even after successful tumor surgery. This is because cancer cells sometimes spread to other […]